TY - JOUR
T1 - Phase II study of carboplatin and etoposide as salvage treatment for patients with metastatic breast cancer
AU - Ron, Ilan G.
AU - Vishne, Tal H.
AU - Kraminsky, Natalie
AU - Bar-Am, Amiram
AU - Inbar, Moshe J.
PY - 1999/2
Y1 - 1999/2
N2 - A phase II study of carboplatin and etoposide as salvage polychemotherapy in metastatic, infiltrating breast carcinoma was carried out with 25 multiply pretreated patients. Six of 25 patients (24%) had a partial response that lasted an average of 3.5 months; of the six responders, four had undergone either four or five previous chemotherapeutic treatments. Eight of 25 patients (32%) had stable disease, and 11 (44%) manifested disease progression. The median survival from time of entry to the salvage protocol was 8 months. There were treatment responses in lung, chest wall, liver, and skeleton. The most common side effects were leukopenia (68% of 25 patients), thrombocytopenia (56%), anemia (40%), fever (28%), and weakness (16%). Carboplatin combined with etoposide may be an effective and tolerable salvage regimen in advanced breast cancer.
AB - A phase II study of carboplatin and etoposide as salvage polychemotherapy in metastatic, infiltrating breast carcinoma was carried out with 25 multiply pretreated patients. Six of 25 patients (24%) had a partial response that lasted an average of 3.5 months; of the six responders, four had undergone either four or five previous chemotherapeutic treatments. Eight of 25 patients (32%) had stable disease, and 11 (44%) manifested disease progression. The median survival from time of entry to the salvage protocol was 8 months. There were treatment responses in lung, chest wall, liver, and skeleton. The most common side effects were leukopenia (68% of 25 patients), thrombocytopenia (56%), anemia (40%), fever (28%), and weakness (16%). Carboplatin combined with etoposide may be an effective and tolerable salvage regimen in advanced breast cancer.
KW - Carboplatin
KW - Etoposide
KW - Metastatic breast cancer
KW - Salvage therapy
UR - http://www.scopus.com/inward/record.url?scp=0033508079&partnerID=8YFLogxK
U2 - 10.1097/00000421-199902000-00009
DO - 10.1097/00000421-199902000-00009
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 10025377
AN - SCOPUS:0033508079
SN - 0277-3732
VL - 22
SP - 35
EP - 37
JO - American Journal of Clinical Oncology: Cancer Clinical Trials
JF - American Journal of Clinical Oncology: Cancer Clinical Trials
IS - 1
ER -